Report Sections

See All Reports

  • HP:0001649: Tachycardia
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001649: Tachycardia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (3)


    Name (Synonyms) Correlation
    drug4494 further processing of health data Wiki 0.71
    drug69 50 mg/mL Virazole Wiki 0.50
    drug24 100 mg/mL Virazole Wiki 0.50

    Correlated MeSH Terms (24)


    Name (Synonyms) Correlation
    D013610 Tachycardia NIH 1.00
    D002561 Cerebrovascular Disorders NIH 0.71
    D019462 Syncope, Vasovagal NIH 0.71
    Name (Synonyms) Correlation
    D013575 Syncope NIH 0.71
    D054144 Heart Failure, Diastolic NIH 0.71
    D016757 Death, Sudden, Cardiac NIH 0.71
    D013616 Tachycardia, Sinus NIH 0.71
    D017180 Tachycardia, Ventricular NIH 0.71
    D002546 Ischemic Attack, Transient NIH 0.50
    D054143 Heart Failure, Systolic NIH 0.50
    D007022 Hypotension NIH 0.50
    D015673 Fatigue Syndrome, Chronic NIH 0.41
    D003643 Death, NIH 0.35
    D001281 Atrial Fibrillation NIH 0.35
    D016584 Panic Disorder NIH 0.35
    D005356 Fibromyalgia NIH 0.32
    D009203 Myocardial Ischemia NIH 0.32
    D054058 Acute Coronary Syndrome NIH 0.29
    D003327 Coronary Disease NIH 0.27
    D007238 Infarction NIH 0.21
    D006333 Heart Failure NIH 0.20
    D006331 Heart Diseases NIH 0.19
    D020521 Stroke NIH 0.18
    D013577 Syndrome NIH 0.06

    Correlated HPO Terms (11)


    Name (Synonyms) Correlation
    HP:0011703 Sinus tachycardia HPO 0.71
    HP:0012668 Vasovagal syncope HPO 0.71
    HP:0001279 Syncope HPO 0.71
    Name (Synonyms) Correlation
    HP:0004756 Ventricular tachycardia HPO 0.71
    HP:0001645 Sudden cardiac death HPO 0.71
    HP:0002615 Hypotension HPO 0.50
    HP:0002326 Transient ischemic attack HPO 0.50
    HP:0004757 Paroxysmal atrial fibrillation HPO 0.35
    HP:0001658 Myocardial infarction HPO 0.32
    HP:0001635 Congestive heart failure HPO 0.20
    HP:0001297 Stroke HPO 0.18

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Essential Arterial Hypotension and Allostasis Registry

    The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a result of the inappropriate allostatic response to daily life stress. This required a functioning brain orchestrating the evaluation of the threat and choosing the response, this is a mind-mediated phenomenon. If the response is excessive it contributes to high BP, if deficient to low BP, and the BP itself will identify the allostatic pattern, which in turn will play an important role in the development of the comorbidities. To do so, consecutive patients of any age and gender that visit a cardiologist's office in Medellin, Colombia, are recruited. Individuals are classified according to their arterial BP and allostasis and follow them in time to see what kind of diseases develops the most (including BP) in the follow up according to the categorization of the characteristic chosen and after adjustment for confounder's variables. In addition, stress events with their date are registered. HYPOTHESIS The causes of the diseases are multifactorial. Physical, biochemical, psychological, social, and cultural dimensions of development dynamically interact to shape the health development process. A person´s health depends on their: 1. Biological and physiologic systems 2. External and internal environment (a) physical, b) internal behavioural and arousal state as registered by the brain. 3. Their interaction. The allostatic mechanisms to the internal and external stressors (allostatic load) involves a network composed by: 1. Functional systems; mediated by: 1. The Autonomic Nervous System 2. The endocrine system 3. The immune system 2. Structural changes: whenever the internal and/or external stressors are long lasting and/or strength enough, they may induce changes in: 1. Epigenetic, endophenotypes, polyphenism. 2. Plasticity 3. The interaction between a) and b). The network response do not affect exclusively the BP, propitiating the development of comorbidities, which may prompt strategies for prevention, recognition and ultimately, treatment. The allostatic model defines health as a state of responsiveness. The concept of psycho-biotype: The allostasis is the result of both: biological (allostasis) and psychological (psychostasis) abilities. It is proposed that both components behave in similar direction and magnitude. Immune disorders may be associated with the development of cancer. High BP population has a higher sympathetic and lower vagal tone, this has been associated with a decrease in the immune´s system function. Resources and energy depletion: Terms like weathering have been used to describe how exposures to different allostatic loads gradually scrape away at the protective coating that keeps people healthy. It is postulated that High BP individuals have more resources and energy.

    NCT02018497
    Conditions
    1. Blood Pressure
    2. Depression
    3. Panic Attack
    4. Fibromyalgia
    5. POTS
    6. Inappropriate Sinus Tachycardia
    7. Coronary Heart Disease
    8. Acute Coronary Syndrome (ACS)
    9. Acute Myocardial Infarction (AMI)
    10. Cerebrovascular Disease (CVD)
    11. Transient Ischemic Attack (TIA)
    12. Atrial Fibrillation
    13. Diabetes Mellitus
    14. Cancer
    15. Systolic Heart Failure
    16. Diastolic Heart Failure
    17. Chronic Fatigue Syndrome
    18. Syncope
    19. Vasovagal Syncope
    MeSH:Fatigue Syndrome, Chronic Fibromyalgia Syncope Ischemic Attack, Transient Cerebrovascular Disorders Syncope, Vasovagal Heart Failure Atrial Fibrillation Heart Diseases Myocardial Infarction Acute Coronary Syndrome Hypotension Coronary Disease Tachycardia Heart Failure, Diastolic Heart Failure, Systolic Tachycardia, Sinus Syndrome Panic Disorder
    HPO:Abnormal left ventricular function Atrial fibrillation Carotid sinus syncope Congestive heart failure Hypotension Myocardial infarction Paroxysmal atrial fibrillation Right ventricular failure Sinus tachycardia Syncope Tachycardia Transient ischemic attack Vasovagal syncope

    Primary Outcomes

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between Blood pressure group and comorbidities

    Time: A 7-year prospective study

    Description: Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between adaptability group and comorbidities

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between blood pressure group, adaptability group and comorbidities

    Time: A 7-year prospective study

    Secondary Outcomes

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, homoeostasis model assessment (HOMA), total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: HR; PR interval, QRS complex, cQT interval Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between blood pressure group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between blood pressure group, adaptability group, habits anthropometric, metabolic, endocrine, electrocardiographic, Holter, ambulatory arterial blood pressure monitoring.

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: 1) Hyper adaptable, 2) normal adaptability and 3) hypo adaptable. Habits: smoke and drink, exercise Anthropometric variables: Body mass index, waist, hip Metabolic and other variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides; thyrotropine, Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: For metabolic disorders what it matters the most: the anthropometric variables vs blood pressure group vs adaptability group

    Time: A 7-year prospective study

    Description: Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)

    Time: A 7-year prospective study

    Other Outcomes

    Description: Clinical syncope characteristics (age of first syncope, number of syncope episodes, trauma, duration, clinical score, convulse, sphincter relaxation, etc.) Syncope cause Blood pressure group Adaptability group Prognosis

    Measure: Syncope Registry

    Time: Up 100 weeks

    Description: TTT protocol: describe the protocol, the time at positive response, nitroglycerine use, autonomic and hemodynamic variables. TTT outcome for syncope: positive or negative TTT other outcomes: 1) Chronotropic incompetence, 2) arterial orthostatic hypotension, 3) carotid hypersensitivity, 4) POTS, 5) IST The relationship between TTT results and Clinical score for syncope in regard to: syncope behaviour and other orthostatic intolerance entities, symptoms and comorbidities. The relationship between neurally mediated syncope response at the TTT and comorbidities.

    Measure: Tilt table testing (TTT) registry

    Time: Up to 100 weeks

    Description: EPS variables: AH, AV, CL, sino atrial conduction time (SACT), sinus node recovery time (SNRT), corrected sinus node recovery time (CSNRT), response to Isoproterenol, intrinsic heart rate Diagnosis: control, sick sinus syndrome, IST, chronotropic incompetence at the TTT HR at the ECG HR at the Holter monitoring HR at the TTT HRV at the Holter monitoring Syncope, cardiac or neurally mediated HR at the physical treadmill test Relationship with the blood pressure group Relationship with the adaptability group

    Measure: Sinus node function at the electrophysiological study (EPS)

    Time: Up to 100 weeks

    Description: Define how the blood pressure group and/or the adaptability group may add to the already known and include in this registry, in the diagnosis of cardiovascular complications as coronary artery disease, cerebrovascular disease, peripheral artery disease, nephropathy.

    Measure: Score for coronary artery disease

    Time: Up to 200 weeks

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, COPD, and others. Mortality

    Measure: Neurally Mediated Syncope: further of the transient lost of consciousness (TLC)

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Psychiatric variables: Big Five Questionary (BFQ) for personality. Modify of the Coping Scale (Scale of modified coping strategies) Zung questionary for depression and anxiety MINI in those patients with moderate or severe depression and/or anxiety at the Zung questionary

    Measure: Psychobiotype: relationship between biological and psychological variables

    Time: Up to 100 weeks

    Description: High sodium intake in the diet is recognized as a risk factor for hypertension development. Essential hypotension population is advised to increase the sodium (at least 10 grams a day) and water intake (at least 2 liters a day), or as much as possible, several have taken Fludrocortisone (is not a exclusion criteria). Normal blood pressure population are advised to have a normal or low sodium intake. Physical exercise is recommended in both groups. This registry is a good opportunity to test how important sodium diet is to induce hypertension, or if by the contrary adaptability could prevail over high sodium intake in this registry. Blood pressure groups: essential hypotension and normotension and those with new essential hypertension. Adaptability groups. The results will be adjusted for age, gender and BMI.

    Measure: The role of high sodium intake in the development of essential hypertension. Comparison between essential hypotension (high sodium intake) vs normotension population (normal or low sodium intake) in the follow-up.

    Time: 4 years

    Description: Consistent bradycardia in the ECG at the office and normal HR in the holter monitoring or the contrary. There are patients with complaints that may be attributed to bradycardia, low blood pressure, hypothyroidism, or other entities. Some patients very often have bradycardia in the ECG taken in the office and normal HR in the 24 Holter monitoring, the opposite is also possible. Patients with bradycardia (without medication or physiological condition as exersice affecting heart rate) in at least 2 ECG (less 60 bpm) and at least 2 Holter monitoring will be analyzed, Other variables to consider are: Age, gender, blood pressure group, adaptability group, maximum HR in the treadmill test, white coat or masked hypertension, Tilt-Table-test result or syncope cause, Electrophysiological study if available. The acknowledge of this phenomenon could have clinical implications in the diagnosis of sick sinus syndrome and physiopathological ones.

    Measure: White coat effect in the heart rate or masked bradycardia.

    Time: 1 year

    Description: Bradycardia is the classical presentation form for sinus node dysfunction, mainly when associated with symptoms. Chronotropic incompetence is also a manifestation. Absence of medications with effects on the heart rate (HR) must be ruled out. Variables HR at the ECG, Holter monitoring, stress text, and at the physical examination previous to pacemaker implantation, Electrophysiological study (EPS): Basic cycle length, Sino-atrial conduction time, Sinus node recovery time, Corrected sinus node recovery time, Intrinsic HR when available 3. Pacemaker variables: HR at day and night or rest time Percentage of stimulation in A and V chambers 4. Syncope: Clinical characteriscs and clinical score Tilt table test results Trans Thoracic Echocardiogram in rest and or stress text Hypothesis: patients with ANSD will start to decrease the percentage atrial stimulation.

    Measure: Reversible Bradycardia Mimicking Sinus Node Dysfunction as a Manifestation of Subacute Autonomic Nervous System Dysfunction (ANSD).

    Time: 2 years

    Description: A non invasive, beat to beat BP monitoring, with the ability to measure BP, HR, Cardiac Output and Systemic Vascular Resistance (SVR) was started to use in the EHAR registry since May 2017. A description of this variables in the three BP groups will be collected in the data base (DB). This will allow to characterize whether SVR and/or CO maintain BP. Until now BP levels are related with prognosis. In the prognosis model SVR and CO will be add them to know what matter the most: BP levels, SVR and/or CO? In the EHAR registry a collection of the variables recognized as a risk factor for several comorbidities are available to adjust in multivariable analysis.

    Measure: Description of the blood pressure hemodynamic profile at a medical office and their prognostic implications.

    Time: Three years
    2 Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study

    The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

    NCT04368637
    Conditions
    1. Acute Myocardial Infarction
    2. Ventricular Tachycardia
    3. Sudden Cardiac Death
    4. Stroke, Acute
    MeSH:Stroke Myocardial Infarction Tachycardia Tachycardia, Ventricular Death, Sudden, Cardiac Infarction Death
    HPO:Myocardial infarction Stroke Sudden cardiac death Tachycardia Ventricular tachycardia

    Primary Outcomes

    Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.

    Measure: Acute cardiovascular event triggered by COVID-19 stress

    Time: 4 months

    Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.

    Measure: Ventricular tachycardia

    Time: 4 months

    Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance

    Measure: acute stroke

    Time: 4 months

    Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracing

    Measure: Implantable cardioverter defibrillator (ICD) shock

    Time: 4 months

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook